HRP20211261T1 - [1,2,4]triazolo[1,5-a]piridinil supstituirani spojevi indola - Google Patents
[1,2,4]triazolo[1,5-a]piridinil supstituirani spojevi indola Download PDFInfo
- Publication number
- HRP20211261T1 HRP20211261T1 HRP20211261TT HRP20211261T HRP20211261T1 HR P20211261 T1 HRP20211261 T1 HR P20211261T1 HR P20211261T T HRP20211261T T HR P20211261TT HR P20211261 T HRP20211261 T HR P20211261T HR P20211261 T1 HRP20211261 T1 HR P20211261T1
- Authority
- HR
- Croatia
- Prior art keywords
- crxrx
- alkyl
- ch2c
- fluoroalkyl
- hydroxyalkyl
- Prior art date
Links
- -1 [1,2,4]triazolo[1,5-a]pyridinyl Chemical group 0.000 title claims 60
- 150000002475 indoles Chemical class 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 63
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 50
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 31
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 20
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 19
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 16
- 125000003386 piperidinyl group Chemical group 0.000 claims 16
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 15
- 125000002757 morpholinyl group Chemical group 0.000 claims 15
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 14
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 14
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 13
- 125000003566 oxetanyl group Chemical group 0.000 claims 11
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000002393 azetidinyl group Chemical group 0.000 claims 9
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 9
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 8
- 125000002883 imidazolyl group Chemical group 0.000 claims 8
- 125000004193 piperazinyl group Chemical group 0.000 claims 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims 8
- 125000000335 thiazolyl group Chemical group 0.000 claims 8
- 125000001425 triazolyl group Chemical group 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 7
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 7
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 6
- 125000002971 oxazolyl group Chemical group 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims 6
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 125000003831 tetrazolyl group Chemical group 0.000 claims 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000002541 furyl group Chemical group 0.000 claims 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000004965 chloroalkyl group Chemical group 0.000 claims 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 235000019256 formaldehyde Nutrition 0.000 claims 3
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 3
- 125000001041 indolyl group Chemical group 0.000 claims 3
- VMWJCFLUSKZZDX-UHFFFAOYSA-N n,n-dimethylmethanamine Chemical compound [CH2]N(C)C VMWJCFLUSKZZDX-UHFFFAOYSA-N 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 125000003725 azepanyl group Chemical group 0.000 claims 2
- 125000004799 bromophenyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 2
- UHCBBWUQDAVSMS-UHFFFAOYSA-N fluoroethane Chemical compound CCF UHCBBWUQDAVSMS-UHFFFAOYSA-N 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical compound [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- 108091006662 SLC9B1 Proteins 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 102100022894 Sodium/hydrogen exchanger 9B1 Human genes 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000005959 diazepanyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 claims 1
- 125000004372 methylthioethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (14)
1. Spoj sa formulom (I)
[image]
ili njegova sol, gdje:
Ri je H, Cl, -CN, C1-4 alkil, C1-3 fluoroalkil, C1-3 hidroksi-fluoroalkil, -CRz=CH2, C3-6 cikloalkil, -CH2(C3-6 cikloalkil), -C(O)O(C1-3 alkil), ili tetrahidropiranil;
svaki R2 je nezavisno halo, -CN, -OH, -NO2+, C1-3 alkil, C1-2 fluoroalkil, C1-2 cijanoalkil, C1-3 hidroksialkil, C1-3 aminoalkil, -O(CH2)1-2OH, -(CH2)0-4O(C1-4 alkil), C1-3 fluoroalkoksi, -(CH2)1-4O(C1-3 alkil), -O(CH2)1-2OC(O)(C1-3 alkil), -O(CH2)1-2NRxRx, -C(O)O(C1-3 alkil), -C(O)NRyRy, -NRyRy, -NRy(C1-3 fluoroalkil), -NRy(C1-4 hidroksialkil), -NRxCH2(fenil), -NRxS(O)2(C3-6 cikloalkil), -NRxC(O)(C1-3 alkil), -NRx(CH2-ciklopropil), C3-6 cikloalkil, morfolinil, dioksotiomorfolinil, metilpiperidinil, metilpiperazinil, amino-oksadiazolil, imidazolil, triazolil, ili -C(O)(tiazolil);
R3 je:
(a) -Li-A; ili
(b) H, C1-6 alkil, C1-3 fluoroalkil, C1-3 cijanoalkil, C1-6 hidroksialkil, C1-3 hidroksi-fluoroalkil, -CRxRxCRx(OH)CRx=CRxRx, -C=N(NRxRx), -(CRxRx)1-4O(C1-3 alkil), -(CRxRx)1-4O(CRxRx)1-3O(C1-3 alkil), -CH2CH(OH)CH2O(C1-3 alkil), -(CRxRx)1-3S(C1-3 alkil), -(CH2)1-3C(O)OC(CH3)3, -(CRxRx)0-3NRxRy, -(CRxRx)0-3NRx(C1-4 hidroksialkil), -CH2CH(OH)CH2NRxRy, -C(O)H, -C(O)(C1-6 alkil), -C(O)(C1-4 hidroksialkil), -C(O)(C1-3 fluoroalkil), -C(O)(C1-3 kloroalkil), -C(O)(C1-3 cijanoalkil), -(CRxRx)0-3C(O)OH, -C(O)(CH2)0-2O(C1-4 alkil), -C(O)(CRxRx)0-2O(CRxRx)1-2O(C1-3 alkil), -C(O)(CRxRx)0-2O(CRxRx)1-2NRyRy, -C(O)CRxRxS(O)2(C1-3 alkil), -C(O)CRxRxNRxS(O)2(C1-3 alkil), -C(O)CRxRxOC(O)(C1-3 alkil), -C(O)(CRxRx)0-3NRyRy, -C(O)(CRxRx)0-1NRx(C1-3 cijanoalkil), -C(O)(CRxRx)0-2NRy(C1-6 hidroksialkil), -C(O)(CRxRx)0-2NRx(C1-3 fluoroalkil), -C(O)(CRxRx)0-1NRx(C1-5 hidroksi-fluoroalkil), -C(O)(CRxRx)0-1NRx(CH2)1-2O(C1-3 hidroksialkil), -C(O)(CRxRx)0-2NRx(CH2)1-2NRxC(O)(C1-2 alkil), -C(O)(CRxRx)0-2NRx((CRxRx)1-2O(C1-2 alkil)), -C(O)(CRxRx)0-2N((CRxRx)1-2O(C1-2 alkil))2, -C(O)(CRxRx)0-2NRx(CRxRx)1-3NRxRx, -C(O)CRx(NH2)(CRxRx)1-4NRxRx, -C(O)CRx(NH2)(CRxRx)1-4NRxC(O)NRxRx, -C(O)(CRxRx)0-3NRx(CH2)0-1C(O)(C1-3 alkil), -C(O)(CRxRx)0-3N((CH2)0-1C(O)(C1-3 alkil))2, -C(O)(CRxRx)0-1NRx(CH2)0-1C(O)(C1-3 cijanoalkil), -C(O)(CRxRx)0-2NRx(CH2)1-2C(O)NRyRy, -C(O)(CRxRx)1-3C(O)NRyRy, -C(O)(CRxRx)1-3S(O)2NRyRy, -C(O)(CRxRx)0-2NRx(CHRy(CH2OH)), -(CRxRx)1-2C(O)NRyRy, -CH(CN)C(O)NRyRy, -(CRxRx)1-2C(O)NRy(C1-3 fluoroalkil), -(CRxRx)1-2C(O)NRy(C1-4 hidroksialkil), -(CRxRx)1-2C(O)NRy(C1-3 cijanoalkil), -(CRxRx)1-2C(O)NRx(CH2)1-2O(C1-3 alkil), -(CRxRx)1-2C(O)NRxCH(C1-4 alkil)(C1-3 hidroksialkil), -(CRxRx)1-2C(O)NRxCH(C1-3 hidroksialkil)(C3-6 cikloalkil), -(CH2)1-2C(O)NRx(CH2)1-2C(O)NRxRx, -(CH2)1-2C(O)NRx(CH2)1-2S(C1-3 alkil), -(CH2)1-2C(O)NRx(CH2)1-2S(O)2OH, -(CH2)1-2C(O)NRx(CH2)1-2NRxC(O)(C1-3 alkil), -(CH2)1-2C(O)NRx(CH2)1-3NRxRx, -(CH2)1-2C(O)N(CH2CH3)(CH2)1-3NRxRx, -(CRxRx)0-3S(O)2(C1-4 alkil), -(CH2)0-2S(O)2(C1-3 fluoroalkil), -(CRxRx)0-2S(O)2NRyRy, -(CRxRx)0-2NRxS(O)2(C1-3 alkil), -C(O)C(O)OH, -C(O)C(O)NRyRy, ili -C(O)C(O)NRy(CRxRx)1-2NRyRy;
L1 je veza, -(CRxRx)1-2-, -(CRxRx)1-2CRx(OH)-, -(CRxRx)1-20-, -CRxRxC(O)-, -(CRxRx)2NRx(CRxRx)0-1-, -CRxRxC(O)NRx(CRxRx)0-4-, -C(O)(CRxRx)0-3-, -C(O)(CRxRx)0-2NRx(CRxRx)0-2-, -C(O)(CRxRx)0-2N(C1-2 hidroksialkil)(CRxRx)0-2-, -C(O)(CRxRx)0-2NRx(CRxRx)1-2CRx(OH)-, -C(O)(CRxRx)1-2C(O)NRx-, -(CRxRx)0-2C(O)NRx(CRxRx)1-2CRx(OH)-, -(CRxRx)0-2C(O)N(C1-2 hidroksialkil)(CRxRx)1-2-, -C(O)(CRxRx)0-1O-, -C(O)(CRxRx)1-2NHS(O)2-, -C(O)CRx(NH2)CRxRx-, -C(O)C(O)(CRxRx)0-2-, -C(O)NRx(CRxRx)1-2-, ili -S(O)2-;
A je 2-oksa-6-azaspiro[3,3]heptanil, 4-oksaspiro[2.5]oktanil, 7-azaspiro[3.5]nonanil, 8-azabiciklo[3.2.1]oktanil, 8-oksa-3-azabiciklo[3.2.1]oktanil, 9-azabiciklo[3.3.1]nonanil, adamantanil, azepanil, azetidinil, C3-6 cikloalkil, diazepanil, dihidroinonil, dihidropirimidinonil, dioksanil, dioksidotiadiazinanil, dioksidotiazolidinil, dioksidotiomorfolinil, dioksoizotiazolidinil, dioksidotiazinanil, dioksotetrahidrotiofenil, dioksotetrahidrotiopiranil, dioksotiomorfolinil, furanil, imidazolil, imidazolidinonil, indolil, izohinolinil, izoksazolil, morfolinil, morfolinonil, naftalenil, oktahidrociklopenta[b]piranil, oktahidropirolo[3,4-b] piridinil, oksazolidinonil, oksadiazolil, oksazolil, oksetanil, fenil, piperidinil, piperidinonil, piperazinil, piperazinonil, pirazinil, pirazolil, piridazinil, piridazinonil, piridinonil, piridinil, pirimidinil, pirolidinonil, pirolidinil, pirolil, hinolinil, hinolizinonil, tetrahidrofuranil, tetrahidropiranil, tetrahidrotiopiranil, tetrazolil, tiadiazolil, tiazolil, triazolonil, ili triazolil, svaki supstituiran sa -L2-Ra i nula do 4 Rb;
L2 je veza ili -CRxRx-;
Ra je:
(a) H, F, Cl, -CN, -OH, C1-6 alkil, C1-3 fluoroalkil, C1-5 hidroksialkil, -(CH2)0-4O(C1-3 alkil), -(CRxRx)1-3S(C1-3 alkil), -(CRxRx)1-3NHC(O)O(C1-4 alkil), -(CRxRx)1-3NRyRy, -(CRxRx)1-3C(O)NRyRy, -O(C1-3 fluoroalkil), -S(O)2NRxRx, -O(CRxRx)1-3NRxRx, -NHS(O)2(C1-3 alkil), -NRxRx, -NRx(C1-4 alkil), -NRxC(O)(C1-4 alkil), -(CRxRx)0-3C(O)OH, -C(O)(C1-5 alkil), -C(O)(C1-3 fluoroalkil), -C(O)O(C1-4 alkil), -C(O)NH(C1-3 cijanoalkil), -C(O)NRyRy, -C(O)NRxCH2C(O)NRxRx, ili -C(O)NRxCH2CH2NHC(O)(C1-3 alkil);
(b) C3-6 cikloalkil ili -C(O)NH(C3-6 cikloalkil), pri čemu je svaki cikloalkil supstituiran sa nula do 2 supstituenata nezavisno odabrana od -OH, C1-3 alkila, C1-3 hidroksialkila, C1- 3 fluoroalkila, i -C(O)O(C1-3 alkila); ili
(c) A1, -CH2A1, -C(O)A1, -NRxA1, ili -C(O)NRxA1, pri čemu A1 je furanil, imidazolil, indolil, izoksazolil, morfolinil, oktahidropirolo[3,4-c]pirolil, oksazolil, oksetanil, fenil, piperazinil, piperidinil, pirazolil, piridinil, pirimidinil, pirolidinil, pirolil, tetrahidrofuranil, tetrahidropiranil, tiadiazolil, tiazolil, tiofenil, ili triazolil, svaki supstituiran sa nula do tri supstituenata nezavisno odabrana od -OH, C1-3 alkila, C1-3 hidroksialkila, -C(O)(C1-2 alkila), -C(O)O(C1-3 alkila), -NRxRx, fenila, trifluorometil-fenila, -CH2(bromofenila), i -CH2CH2(pirolidinila);
svaki Rb je nezavisno F, -OH, -CH3, -CF3, ili -OCH3;
svaki Rx je nezavisno H ili -CH3;
svaki Ry je nezavisno H ili C1-6 alkil;
Rz je H, C1-2 alkil, ili C1-2 fluoroalkil;
svaki R4 je nezavisno F, -OH, C1-2 alkil, ili -OCH3; ili dva R4 vezana za isti atom ugljika formiraju =O; ili gdje kada m je najmanje 2, dva R4, pri čemu je svaki vezan za različit atom ugljika susjedan atomu dušika u piperidinil prstenu, mogu da formiraju -CH2CH2-most;
svaki R5 je nezavisno F, Cl, -CN, C1-2 alkil, C1-2 fluoroalkil, ili -OCH3;
m je nula, 1, 2, 3, ili 4;
n je nula, 1, ili 2; i
p je nula, 1, 2, 3, ili 4.
2. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, pri čemu:
Ri je H, Cl, -CN, C1-4 alkil, ili C1-2 fluoroalkil;
svaki R2 je nezavisno F, Cl, -CN, -OH, C1-3 alkil, C1-2 fluoroalkil, C1-2 cijanoalkil, C1-3 hidroksialkil, C1-3 aminoalkil, -O(CH2)1-2OH, -O(C1-4 alkil), C1-2 fluoroalkoksi, -(CH2)1-4O(C1-3 alkil), -O(CH2)1-2OC(O)(C1-3 alkil), -O(CH2)1-2NRxRx, -C(O)O(C1-3 alkil), -C(O)NRyRy, -NRyRy, -NRy(C1-3 fluoroalkil), -NRy(C1-4 hidroksialkil), -NRxCH2(fenil), -NRxS(O)2(C3-6 cikloalkil), -NRxC(O)(C1-3 alkil), -NRx(CH2-ciklopropil), C3-6 cikloalkil, morfolinil, dioksotiomorfolinil, metilpiperidinil, metilpiperazinil, amino-oksadiazolil, imidazolil, triazolil, ili -C(O)(tiazolil);
R3 je:
(a) -Li-A; ili
(b) H, C1-6 alkil, C1-3 fluoroalkil, C1-3 cijanoalkil, C1-5 hidroksialkil, -C=N(NRxRx), -(CRxRx)1-2O(C1-2 alkil), -(CRxRx)1-4O(CRxRx)1-3O(C1-3 alkil), -CH2CH(OH)CH2O(C1-3 alkil), -(CRxRx)1-3S(C1-3 alkil), -(CH2)1-3C(O)OC(CH3)3, -(CRxRx)0-3NRxRy, -(CRxRx)0-3NRx(C1-4 hidroksialkil), -CH2CH(OH)CH2NRxRy, -C(O)(C1-6 alkil), -C(O)(C1-4 hidroksialkil), -C(O)(C1-3 fluoroalkil), -C(O)(C1-3 kloroalkil), -C(O)(C1-3 cijanoalkil), -(CRxRx)0-3C(O)OH, -C(O)(CH2)0-2O(C1-4 alkil), -C(O)(CRxRx)0-2O(CRxRx)1-2O(C1-3 alkil), -C(O)(CH2)O-2O(CH2)1-2HRyRy, -C(O)CRxRxS(O)2(C1-2 alkil), -C(O)CRxRxNRxS(O)2(C1-2 alkil), -C(O)CRxRxOC(O)(C1-3 alkil), -C(O)(CRxRx)0-2NRyRy, -C(O)(CRxRx)0-2NRx(C1-2 cijanoalkil), -C(O)(CRxRx)0-2NRy(C1-6 hidroksialkil), -C(O)(CRxRx)0-2NRx(C1-3 fluoroalkil), -C(O)(CRxRx)0-1NRx(C1-5 hidroksi-fluoroalkil), -C(O)(CRxRx)0-1NRx((CRxRx)1-2O(C1-2 alkil)), -C(O)(CRxRx)0-1NRx(CH2)1-2O(C1-3 hidroksialkil), -C(O)(CRxRx)0-1NRx(CH2)1-2NRxC(O)(C1-2 alkil), -C(O)(CRxRx)0-2NRx((CRxRx)1-2O(C1-2 alkil)), -C(O)(CRxRx)0-1NRx(CRxRx)1-3NRxRx, -C(O)CRx(NH2)(CRxRx)1-4NRxRx, -C(O)CRx(NH2)(CRxRx)1-4NRxC(O)NRxRx, -C(O)(CRxRx)0-3NRx(CH2)0-1C(O)(C1-3alkil), -C(O)(CRxRx)0-1NRx(CH2)0-1C(O)(C1-3 cijanoalkil), -C(O)(CRxRx)0-2NRx(CH2)1-2C(O)NRyRy, -C(O)(CRxRx)0-2NRx(CHRy(CH2OH)), -(CRxRx)1-2C(O)NRyRy, -(CRxRx)1-2C(O)NRy(C1-3 fluoroalkil), -(CRxRx)1-2C(O)NRy(C1-4 hidroksialkil), -(CRxRx)1-2C(O)NRx(C1-3 cijanoalkil), -CH(CN)C(O)NRyRy, -(CRxRx)1- 2C(O)NRx(CH2)1-2O(C1-3 alkil), -(CRxRx)1-2C(O)NRxCH(C1-4 alkil)(C1-3 hidroksialkil), -(CH2)1-2C(O)NRx(CH2)1-2C(O)NRxRx, -(CH2)1-2S(O)2NRx(CH2)1-2S(C1-2 alkil), -(CH2)1-2C(O)NRx(CH2)1-2S(O)2OH, -(CH2)1-2C(O)NRx(CH2)1-2NRxC(O)(C1-3 alkil), -(CH2)1-2C(O)NRx(CH2)1-3NRxRx,-(CH2)1-2C(O)N(CH2CH3)(CH2)1-3NRxRx, -(CRxRx)1-3S(O)2(C1-4 alkil), -(CH2)0-2S(O)2(C1-3 fluoroalkil), -(CH2)1-2S(O)2NRyRy, -C(O)C(O)OH, -C(O)C(O)NRyRy, ili -C(O)C(O)NRy(CRxRx)1-2NRyRy;
L1 je veza, -CRxRx-, -CRxRxC(O)-, -CRxRxC(O)NRx-, ili -C(O)(CRxRx)0-2-;
A je prsten odabran od azetidinila, C3-6 cikloalkila, dioksotetrahidrotiopiranila, dioksidotiadiazinanila, dioksidotiomorfolinila, furanila, imidazolila, izohinolinila, morfolinila, oksazolila, 2-oksa-6-azaspiro[3.3]heptanila, oksetanila, fenila, piperazinila, piperidinila, pirazinila, pirazolila, piridinila, pirolidinila, pirolila, hinolinila, tetrahidrofuranila, tetrahidropiranila, tetrazolila, tiadiazolila, tiazolila, i triazolila, svaki supstituiran sa -L2-Ra i nula do 4 Rb;
L2 je veza ili -CRxRx-;
Ra je:
(a) H, -CN, -OH, C1-3 alkil, C1-2 fluoroalkil, C1-3 hidroksialkil, -(CH2)1-2O(C1-3 alkil), -(CRxRx)1-3NHC(O)O(C1-4 alkil), -(CRxRx)1-3NH2, -(CRxRx)1-3NRx(C1-4 alkil), -O(C1-2 fluoroalkil), -S(O)2NRxRx, -NHS(O)2(C1-3 alkil), -NRxRx, -NRx(C1-4 alkil), -(CRxRx)1-2C(O)OH, -C(O)OH, -C(O)(C1-3 alkil), -C(O)O(C1-3 alkil), -C(O)NRx(C1-2 alkil), -C(O)N(C1-3 alkil)2, -C(O)NRxCH2C(O)NRxRx, ili -C(O)NRxCH2CH2NHC(O)(C1-3 alkil);
(b) C3-6 cikloalkil ili -C(O)NH(C3-6 cikloalkil), gdje svaki cikloalkil je supstituiran sa nula do 2 supstituenta nezavisno odabrana od -OH, C1-3 alkila, C1-3 hidroksialkila, C1-3 fluoroalkila, i -C(O)O(C1-3 alkila); ili
(c) A1, -CH2A1, -C(O)A1, ili -C(O)NHA1, pri čemu A1 je furanil, imidazolil, indolil, izoksazolil, oktahidropirolo[3,4-c]pirolil, oksazolil, oksetanil, fenil, piperazinil, piperidinil, pirazolil, piridinil, pirimidinil, pirolidinil, pirolil, tetrahidrofuranil, tetrahidropiranil, tiadiazolil, tiazolil, tiofenil, ili triazolil, svaki supstituiran sa nula do tri supstituenata nezavisno odabrana od -OH, C1-3 alkila, C1-3 hidroksialkila, -C(O)(C1-2 alkila), -C(O)O(C1-3 alkila), -NRxRx, fenila, trifluorometil-fenila, -CH2(bromofenila), i -CH2CH2(pirolidinila);
R5 je F, Cl, -CN, C1-2 alkil, ili -OCH3;
svaki Rb je nezavisno -CH3 ili -CF3;
svaki Rx je nezavisno H ili -CH3;
svaki Ry je nezavisno H ili C1-5 alkil;
m je nula, 1, ili 2;
n je nula ili 1; i
p je nula, 1, ili 2.
3. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, pri čemu:
R1 je -CH2CH3, -CH(CH3)2, ili -CH2CHF2;
svaki R2 je nezavisno F, Cl, -CN, -CH3, -CH2CH3, -CH(CH3)2, -CF3, -CH2CN, -CH2OH, -CH2CH2OH, -CH(CH3)OH, -C(CH3)2OH, -OCH2CH2OH, -OCH3, -OCH2CH3, -OCH2CH(CH3)2, -OCHF2, -CH2OCH3, -CH2OCH2CH3, -OCH2CH2OC(O)CH3, -NH2, -NH(CH2CH3), -NH(CH2CF3), -NH(CH2C(CH3)2OH), -NHCH2(fenil), -NHS(O)2(ciklopropil), ciklopropil, morfolinil, dioksotiomorfolinil, ili metilpiperazinil;
R3 je H, C1-5 alkil, C2-3 fluoroalkil, C1-3 cijanoalkil, C2-5 hidroksialkil, -CH2CH2OCH3, -CH2N(CH3)2, -CH2CH2NH(CH3), -C=N(NH2), -C(O)CH3, -C(O)CH(CH2CH3)2, -C(O)CH2CF3, -C(O)CH2CH2OH, -C(O)CH(CH3)OH, -C(O)CH2CH(CH3)OH, -C(O)CH2C(CH3)2OH, -C(O)CH2CN, -C(O)CH2CH2CN, -C(O)OC(CH3)3, -C(O)CH2OCH3, -C(O)CH2CH2OCH3, -C(O)OCH2CH2NH2, -C(O)OCH2CH2N(CH3)2, -C(O)OCH2CH2N(CH2CH3)2, -C(O)CH2S(O)2CH3, -C(O)CH2CH2S(O)2CH3, -C(O)CH2NHS(O)2CH3, -C(O)NH(CH2C(CH3)3), -C(O)CH2NH(CH3), -C(O)CH2NH(CH2CH3), -C(O)CH2NH(CH2CH2CH3), -C(O)CH2NH(CH2CH2CH3), -C(O)CH2NH(CH(CH3)2), -C(O)CH2NH(CH2CH(CH3)2), -C(O)CH2NH(C(CH3)3), -C(O)CH2N(CH3)2, -C(O)CH2N(CH3)(CH2CH3), -C(O)CH2N(CH3)(CH2CH2CH3), -C(O)CH2N(CH3)(CH(CH3)2), -C(O)CH2N(CH3)(CH2CH(CH3)2), -C(O)CH2N(CH2CH3)2, -C(O)CH2CH2NH(CH3), -C(O)CH2CH2NH(CH2CH3), -C(O)CH2CH2NH(CH2CH2CH3), -C(O)CH2CH2NH(CH(CH3)2), -C(O)CH2CH2NH(CH2C(CH3)3), -C(O)CH2CH2N(CH3)2, -C(O)CH2CH2N(CH3)(CH2CH3), -C(O)CH2CH2N(CH3)(CH2CH2CH3), -C(O)CH2CH2N(CH3)(CH(CH3)2), -C(O)CH(CH3)NH(CH3), -C(O)CH2NH(CH2CN), -C(O)CH2N(CH3)(CH2CH2CN), -C(O)CH2NH(CH2C(O)NH2), -C(O)CH2N(CH3)(CH2C(O)N(CH3)2), -C(O)CH2CH2NH(CH2C(O)NH2), -C(O)CH2CH2N(CH3)CH2C(O)N(CH3)2, -C(O)CH2NH(CH2CH2OH), -C(O)CH2N(CH3)(CH2CH2OH), -C(O)CH2CH2NH(CH2CH2OH), -C(O)CH2CH2N(CH3)(CH2CH2OH), -C(O)CH2NH(CH2CH2F), -C(O)CH2NH(CH2CF3), -C(O)CH2CH2NH(CH2CH2F), -C(O)CH2NH(CH2CH2OCH3), -C(O)CH2N(CH3)(CH2CH2OCH3), -C(O)CH2CH2NH(CH2CH2OCH3), -C(O)CH2CH2N(CH3)(CH2CH2OCH3), -C(O)CH2N(CH2CH2OCH3)2, -C(O)CH2CH2CH2S(O)2NH2, -CH2C(O)NH2, -CH2C(O)NH(CH3), -CH2C(O)N(CH3)2, -CH2C(O)NH(CH2CH3), -CH2C(O)N(CH3)(CH2CH3), -CH2C(O)N(CH2CH3)2, -CH2C(O)NH(CH2CH2CH3), -CH2C(O)NH(CH(CH3)2), -CH(CN)C(O)N(CH3)2, -CH2C(O)NH(CH2CH2CF3), -CH2C(O)N(CH3)(CH2CH2OH), -CH2C(O)N(CH3)(CH2CH2OH), -CH2C(O)N(CH2CH3)(CH2CH2OH), -CH2C(O)N(CH2CH2CH3)(CH2CH2OH), -CH2C(O)N(CH3)(CH2CH2CH2OH), -CH2C(O)NH(CH2C(CH3)2OH), -CH2C(O)N(CH2CH(CH3)CH2CH3)(CH2CH2OH), -CH2C(O)NH(CH2CH2CN), -CH2C(O)N(CH3)(CH2CH2CN), -CH2C(O)N(CH3)(CH2CH2OCH3), -CH(CH3)CH2S(O)2(CH2CH2CH2CH3), -CH2CH2S(O)2NH2, -CH2CH2S(O)2NH(CH3), -CH2CH2S(O)2N(CH3)2, -CH(CH3)CH2S(O)2N(CH2CH3)2, -CH2CH2NHS(O)2CH3, -CH2CH2N(CH3)S(O)2CH3, -CH2C(O)NH(CH2CH2SCH3), -C(O)NH(CH2CH2NH2), -C(O)N(CH3)CH2CH2NH2, -C(O)NH(CH2CH2N(CH3)2), -C(O)NH(CH2CH2CH2NH2), -CH2CH2S(O)2CH3, -CH2CH2CH2S(O)2CH3, -CH(CH3)CH2S(O)2CH3, -C(O)CH2(2-oksa-6-azaspiro[3.3]heptanil), -C(O)CH2(piperazinonil), -C(O)CH2(piperazinil), -C(O)CH2(piperidinil), -C(O)CH2(pirimidinil), -C(O)CH2(pirolidinil), -C(O)CH2(tetrahidropiranil), -C(O)CH2(tetrazolil), -C(O)CH2(tiazolil), -C(O)CH2CH2(azepanil), -C(O)CH2CH2(azetidinil), -C(O)CH2CH2(dioksotiomorfolinil), -C(O)CH2CH2(morfolinil), -C(O)CH2CH2(piperidinonil), -C(O)CH2CH2(piperidinil), -C(O)CH2CH2(pirolidinonil), -C(O)CH2CH2(pirolidinil), -C(O)CH2CH(CH3)(oksetanil), -C(O)NH(piperidinil), -C(O)NH(pirolidinil, -C(O)CH2NH(ciklopropil), -C(O)CH2NH(ciklobutil), -C(O)CH2NH(cikloheksil), -C(O)CH2NH(oksetanil), -C(O)CH2N(CH3)(ciklopropil), -C(O)CH2N(CH3)(cikloheksil), -C(O)CH2CH2NH(ciklopentil), -C(O)CH2CH2NH(cikloheksil), -C(O)CH2CH2N(CH3)(cikloheksil), -C(O)CH2N(CH2CH2OH)(ciklopropil), -C(O)CH2CH2N(CH2CH2OH)(ciklopropil), -C(O)CH2CH2NH(CH2(ciklopropil)), -C(O)CH2CH2NH(CH2(tetrahidrofuranil)), -C(O)CH2NH(CH2(ciklopropil)), -C(O)CH2NH(CH2(cikloheksil)), -C(O)CH2NH(CH2(tetrahidrofuranil)), -C(O)NH(CH2(piperidinil)), -C(O)NH(CH2(pirolidinil)), -C(O)NH(CH2CH2(morfolinil)), -C(O)NH(CH2CH2(piperazinil)), -C(O)NH(CH2CH2(piperidinil)), -C(O)NH(CH2CH2(pirolidinil)), -C(O)O(azetidinil), -C(O)O(piperidinil), -C(O)O(pirolidinil), -C(O)OCH2(azetidinil), -C(O)OCH2(piperidinil), -C(O)OCH2(pirolidinil), -C(O)OCH2CH2(dioksotiomorofolinil), -C(O)OCH2CH2(imidazolil), -C(O)OCH2CH2(morfolinil), -C(O)OCH2CH2(piperazinil), -C(O)OCH2CH2(piperidinil), -C(O)OCH2CH2(pirolidinil), -CH2(ciklopropil), -CH2(dioksotetrahidrotiopiranil), -CH2(imidazolil), -CH2(izoksazolil), -CH2(morfolinil), -CH2(oksadiazolil), -CH2(oksazolil), -CH2(oksetanil), -CH2(fenil), -CH2(pirazinil), -CH2(pirazolil), -CH2(piridazinil), -CH2(pirimidinil), -CH2(tetrazolil), -CH2(tiadiazolil), -CH2(tiazolil), -CH2(triazolonil), -CH2(triazolil), -CH(CH3)(pirazolil), -CH(CH3)(piridazinil), -CH(CH3)(pirimidinil), -CH2CH2(dioksoizotiazolidinil), -CH(CN)(oksetanil), -CH(CH3)CH2S(O)2(morfolinil), -CH(CH3)CH2S(O)2(piperidinil), -CH2C(O)(morfolinil), -CH2C(O)(2-oksa-6-azaspiro[3.3]heptanil), -CH2C(O)(azetidinil), -CH2C(O)(dioksidotiadiazinanil), -CH2C(O)(dioksidotiazolidmil), -CH2C(O)(dioksidotiomorfolinil), -CH2C(O)(dioksotiomorfolinil), -CH2C(O)(2-oksa-6-azaspiro[3.3]heptanil), -CH2C(O)(piperazinonil), -CH2C(O)(piperazinil), -CH2C(O)(piperidinil), -CH2C(O)(pirolidinil), -CH2C(O)NHCH(CH2CH2OH)(ciklopropil), -CH2C(O)N(CH2CH2OH)(ciklopropil), -CH2C(O)N(CH3)(ciklopropil), -CH2C(O)N(CH3)(tetrahidrofuranil), -CH2C(O)N(CH3)(tetrahidropiranil), -CH2C(O)N(CH3)CH2CH2(ciklopentil), -CH2C(O)N(CH3)CH2CH2(pirazolil), -CH2C(O)NH(azetidinil), -CH2C(O)NH(CH2(oksetanil)), -CH2C(O)NH(ciklobutil), -CH2C(O)NH(ciklopropil), -CH2C(O)NH(oksetanil), -CH2C(O)NH(tetrahidropiranil), -CH2CH2S(O)2(morfolinil), ili -CH2CH2S(O)2(fenil);
m je nula, 1, 2, ili 3;
n je nula; i
p je nula, 1 ili 2.
4. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, pri čemu:
R1 je -CH(CH3)2;
svaki R2 je nezavisno -CH3, -OCH3, ili -CH2OCH3;
R3 je H, -CH(CH3)2, -CH(CH3)2, -CH2CH(CH3)2, -CH2CN, -CH2CH2CN, -CH2CH2CH2CN, -CH2C(CH3)2OH, -C(O)CH3, -C(O)CH(CH2CH3)2, -C(O)CH2OCH3, -C(O)CH2CH2OCH3, -C(O)CH2CH(CH3)OH, -C(O)CH2CN, -C(O)CH2CH2CN, -C(O)CH(CH3)NH(CH3), -C(O)CH2NH(CH3), -C(O)CH2N(CH3)2, -C(O)CH2NHCH2CH2CH3, -C(O)CH2NHCH(CH3)2, -C(O)CH2NHC(CH3)3, -C(O)CH2N(CH3)CH(CH3)2, -C(O)CH2NHCH2CH2OCH3, -CH2C(O)NH2, -CH2C(O)NH(CH3), -CH2C(O)N(CH3)CH2CH3, -CH2C(O)NHCH2CH2CH3, -CH2C(O)NH(CH(CH3)2), -CH2C(O)N(CH3)2, -CH2C(O)N(CH2CH3)2, -CH2CH2S(O)2CH3, -CH2CH2S(O)2NH2, -CH2C(O)NH(ciklobutil), -CH2C(O)NH(ciklopropil), -CH2C(O)NH(metiloksetanil), -CH2C(O)N(CH3)(ciklopropil), oksetanil, tetrahidropiranil, dioksotetrahidrotiopiranil, -CH2(oksazolil), -CH2(pirazolil), -CH2(tetrazolil), -CH2(triazolil), -CH2(metiltriazolil), -CH2C(O)(2-oksa-6-azaspiro[3.3]heptanil), -CH2C(O)(azetidinil), -CH2C(O)(dioksidotiadiazinanil), -CH2C(O)(dioksidotiomorfolinil), -CH2C(O)(morfolinil), -CH2C(O)(metoksietilpiperazinil), -CH2C(O)(piperidinil), -CH2C(O)(hidroksipiperidinil), -CH2C(O)(pirolidinil), -CH2C(O)(hidroksipirolidinil), -C(O)(azetidinil), -C(O)(metilciklopropil), -C(O)(metiloksetanil), ili -C(O)CH2(morfolinil);
m je nula;
n je nula; i
p je nula, 1 ili 2.
5. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, pri čemu:
R3 je -Li-A.
6. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, pri čemu: R3 je H, C1-6 alkil, C1-3 fluoroalkil, C1-3 cijanoalkil, C1-6 hidroksialkil, C1-3 hidroksi-fluoroalkil, -CRxRxCRx(OH)CRx=CRxRx, -(CRxRx)1-4O(C1-3 alkil), -(CRxRx)1-4O(CRxRx)1-3O(C1-3 alkil), -CH2CH(OH)CH2O(C1-3 alkil), -(CRxRx)1-3S(C1-3 alkil), -(CH2)1-3C(O)OC(CH3)3, -(CRxRx)0-3NRxRy, -(CRxRx)0-3NRx(C1-4 hidroksialkil), -CH2CH(OH)CH2NRxRy, -C(O)H, -C(O)(C1-6 alkil), -C(O)(C1-3 hidroksialkil), -C(O)(C1-3 fluoroalkil), -C(O)(C1-3 kloroalkil), -C(O)(C1-3 cijanoalkil), -(CRxRx)0-3C(O)OH, -C(O)(CH2)0-2O(C1-4 alkil), -C(O)(CRxRx)0-2O(CRxRx)1-2O(C1-3 alkil), -C(O)CRxRxS(O)2(C1-3 alkil), -C(O)CRxRxNRxS(O)2(C1-3 alkil), -C(O)CRxRxOC(O)(C1-3 alkil), -C(O)(CRxRx)0-3NRyRy, -C(O)(CRxRx)0-1NRx(C1-3 cijanoalkil), -C(O)(CRxRx)0-2NRy(C1-6 hidroksialkil), -C(O)(CRxRx)0-1NRx(C1-3 fluoroalkil), -C(O)(CRxRx)0-1NRx(C1-5 hidroksi-fluoroalkil), -C(O)(CRxRx)0-1NRx(CH2)1-2O(C1-3 hidroksialkil), -C(O)(CRxRx)0-1NRx(CH2)1-2NRxC(O)(C1-2 alkil), -C(O)(CRxRx)0-1NRx((CRxRx)1-2O(C1-2alkil)), -C(O)CRx(NH2)(CRxRx)1-4NRxRx, -C(O)CRx(NH2)(CRxRx)1-4NRxC(O)NRxRx, -C(O)(CRxRx)0-3NRx(CH2)0-1C(O)(C1-3 alkil), -C(O)(CRxRx)0-1NRx(CH2)0-1C(O)(C1-3 cijanoalkil), -C(O)(CRxRx)0-1NRx(CH2)1-2C(O)NRyRy, -C(O)(CRxRx)0-1NRx(CHRy(CH2OH)), -(CRxRx)1-2C(O)NRyRy, -(CRxRx)1-2C(O)NRy(C1-3 fluoroalkil), -(CRxRx)1-2C(O)NRy(C1-4 hidroksialkil), -(CRxRx)1-2C(O)NRy(C1-3 cijanoalkil), -(CRxRx)1-2C(O)NRx(CH2)1-2O(C1-3 alkil), -(CRxRx)1-2C(O)NRxCH(C1-4 alkil)(C1-3 hidroksialkil), -(CH2)1-2C(O)NRx(CH2)1-2C(O)NRxRx,-(CH2)1-2C(O)NRx(CH2)1-2S(O)2OH,-(CH2)1-2C(O)NRx(CH2)1-2NRxC(O)(C1-3 alkil), -(CH2)1-2C(O)NRx(CH2)1-3NRxRx, -(CH2)1-2C(O)N(CH2CH3)(CH2)1-3NRxRx, -(CH2)0-2S(O)2(C1-4 alkil), -(CH2)0-2S(O)2(C1-3 fluoroalkil), -(CH2)0-2S(O)2NRxRx, -C(O)C(O)OH, -C(O)C(O)NRyRy, ili -C(O)C(O)NRy(CRxRx)1-2NRyRy.
7. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, pri čemu:
R1 je -CH(CH3)2;
svaki R2 je nezavisno odabran od -CH3 ili -OCH3;
R3 je H, -CH2C(O)NH2, -CH2C(O)NH(CH3), -CH2C(O)N(CH3)2, ili -CH2CH2S(O)2CH3;
m je nula;
n je nula; i
p je 1 ili 2.
8. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, pri čemu:
R1 je -CH(CH3)2;
svaki R2 je nezavisno odabran od F, Cl, -CN, -CH3, ili -CF3;
R3 je -CH2CN, -CH2C(CH3)2OH, -C(O)CH2NH(CH3), -C(O)CH2N(CH3)2, -CH2C(O)N(CH3)2, ili -CH2CH2S(O)2CH3;
m je nula;
n je nula; i
p je 1 ili 2.
9. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, pri čemu je navedeni spoj:
[image]
10. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, pri čemu je navedeni spoj:
[image]
11. Farmaceutska kompozicija koja sadrži spoj u skladu sa bilo kojim patentnim zahtjevom 1-10 ili njegova farmaceutski prihvatljiva sol; i farmaceutski prihvatljiv nosač.
12. Spoj u skladu sa bilo kojim od patentnih zahtjeva 1 do 10 ili njegova farmaceutski prihvatljiva sol, ili kompozicija u skladu sa patentnim zahtjevom 11 za primjenu u terapiji.
13. Spoj u skladu sa bilo kojim od patentnih zahtjeva 1-10 ili njegova farmaceutski prihvatljiva sol, za primjenu u terapiji u liječenju autoimune bolesti ili kronične inflamatorne bolesti.
14. Spoj ili njegova farmaceutski prihvatljiva sol za primjenu u skladu sa patentnim zahtjevom 13, pri čemu je navedena autoimuna bolest ili kronična inflamatorna bolest odabrana od sustavnog eritemskog lupusa (SLE), reumatoidnog artritisa, multiple skleroze (MS), i Sjӧgrenovog sindroma.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201611022328 | 2016-06-29 | ||
US15/635,055 US10071079B2 (en) | 2016-06-29 | 2017-06-27 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
EP17737442.8A EP3478682B1 (en) | 2016-06-29 | 2017-06-28 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
PCT/US2017/039633 WO2018005586A1 (en) | 2016-06-29 | 2017-06-28 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20211261T1 true HRP20211261T1 (hr) | 2021-11-26 |
HRP20211261T8 HRP20211261T8 (hr) | 2022-01-21 |
Family
ID=60805851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211261TT HRP20211261T8 (hr) | 2016-06-29 | 2021-08-04 | [1,2,4]triazolo[1,5-a]piridinil supstituirani spojevi indola |
Country Status (31)
Country | Link |
---|---|
US (8) | US10071079B2 (hr) |
EP (1) | EP3478682B1 (hr) |
JP (1) | JP6995067B6 (hr) |
KR (1) | KR102473482B1 (hr) |
CN (1) | CN109641895B (hr) |
AR (1) | AR108905A1 (hr) |
AU (1) | AU2017287902B2 (hr) |
BR (1) | BR112018077119A2 (hr) |
CA (1) | CA3029620A1 (hr) |
CL (1) | CL2018003821A1 (hr) |
CO (1) | CO2019000686A2 (hr) |
CY (1) | CY1124514T1 (hr) |
DK (1) | DK3478682T3 (hr) |
EA (1) | EA037530B1 (hr) |
ES (1) | ES2886964T3 (hr) |
HR (1) | HRP20211261T8 (hr) |
HU (1) | HUE056091T2 (hr) |
IL (1) | IL263961B (hr) |
LT (1) | LT3478682T (hr) |
MX (1) | MX2018015422A (hr) |
MY (1) | MY196474A (hr) |
PE (1) | PE20190324A1 (hr) |
PL (1) | PL3478682T3 (hr) |
PT (1) | PT3478682T (hr) |
RS (1) | RS62292B1 (hr) |
SG (1) | SG11201811590RA (hr) |
SI (1) | SI3478682T1 (hr) |
TW (1) | TWI636053B (hr) |
UY (1) | UY37310A (hr) |
WO (1) | WO2018005586A1 (hr) |
ZA (1) | ZA201900571B (hr) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
AU2017307208B2 (en) | 2016-07-30 | 2021-01-21 | Bristol-Myers Squibb Company | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors |
EP3510024B1 (en) | 2016-09-09 | 2021-11-17 | Bristol-Myers Squibb Company | Pyridyl substituted indole compounds |
BR112019007450A2 (pt) | 2016-10-14 | 2020-07-07 | Precision Biosciences, Inc. | meganucleases modificadas específicas para sequências de reconhecimento no genoma do vírus da hepatite b |
WO2019028301A1 (en) * | 2017-08-04 | 2019-02-07 | Bristol-Myers Squibb Company | INDOLE COMPOUNDS SUBSTITUTED WITH [1,2,4] TRIAZOLO [4,3-A] PYRIDINYL |
ES2909401T3 (es) | 2017-08-04 | 2022-05-06 | Bristol Myers Squibb Co | Compuestos de indol sustituidos útiles como inhibidores de TLR7/8/9 |
WO2019099336A1 (en) * | 2017-11-14 | 2019-05-23 | Bristol-Myers Squibb Company | Substituted indole compounds |
SG11202005513TA (en) * | 2017-12-15 | 2020-07-29 | Bristol Myers Squibb Co | Substituted indole ether compounds |
AU2018390543A1 (en) * | 2017-12-19 | 2020-08-06 | Bristol-Myers Squibb Company | 6-azaindole compounds |
EA202091483A1 (ru) | 2017-12-19 | 2020-10-28 | Бристол-Маерс Сквибб Компани | Амидзамещенные индольные соединения, пригодные в качестве ингибиторов tlr |
SG11202005696YA (en) * | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | Substituted indole compounds useful as tlr inhibitors |
WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
SG11202005694RA (en) | 2017-12-20 | 2020-07-29 | Bristol Myers Squibb Co | Amino indole compounds useful as tlr inhibitors |
SG11202005733QA (en) | 2017-12-20 | 2020-07-29 | Bristol Myers Squibb Co | Diazaindole compounds |
US11420958B2 (en) | 2017-12-20 | 2022-08-23 | Bristol-Myers Squibb Company | Aryl and heteroaryl substituted indole compounds |
EP3752505B1 (en) | 2018-02-12 | 2023-01-11 | F. Hoffmann-La Roche AG | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
CN111788204B (zh) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | 作为hbv复制抑制剂的取代吡咯嗪化合物 |
US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
CA3093888A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’-環二核苷酸 |
US11713327B2 (en) | 2018-06-12 | 2023-08-01 | Hoffmann-La Roche Inc. | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
CN112585134A (zh) * | 2018-06-13 | 2021-03-30 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的吡啶基杂环基化合物 |
EP3826724B1 (en) | 2018-07-23 | 2022-10-05 | F. Hoffmann-La Roche AG | Novel piperazine compounds for the treatment of autoimmune disease |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
WO2020048583A1 (en) | 2018-09-04 | 2020-03-12 | F. Hoffmann-La Roche Ag | Benzothiazole compounds for the treatment of autoimmune diseases |
CN112654618A (zh) | 2018-09-06 | 2021-04-13 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的新型环脒化合物 |
WO2020086505A1 (en) * | 2018-10-24 | 2020-04-30 | Bristol-Myers Squibb Company | Substituted indole dimer compounds |
US20210403468A1 (en) * | 2018-10-24 | 2021-12-30 | Bristol-Myers Squibb Company | Substituted indole and indazole compounds |
LT3873903T (lt) | 2018-10-31 | 2024-05-10 | Gilead Sciences, Inc. | Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai |
CA3116347A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
WO2020178769A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
JP7350872B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 3’3’-環状ジヌクレオチドおよびそのプロドラッグ |
TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
JP2022532568A (ja) * | 2019-05-07 | 2022-07-15 | ブリストル-マイヤーズ スクイブ カンパニー | プロドラッグ化合物 |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
CN110146631B (zh) * | 2019-06-25 | 2021-11-12 | 山西康宝生物制品股份有限公司 | 一种药用材料中聚乙二醇单甲醚残留量的检测方法 |
WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
CN117843811A (zh) | 2019-09-30 | 2024-04-09 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
WO2021067657A1 (en) * | 2019-10-04 | 2021-04-08 | Bristol-Myers Squibb Company | Substituted carbazole compounds |
WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
TW202200161A (zh) | 2020-03-20 | 2022-01-01 | 美商基利科學股份有限公司 | 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法 |
JP2023530264A (ja) | 2020-06-11 | 2023-07-14 | ブリストル-マイヤーズ スクイブ カンパニー | 皮膚エリテマトーデスを治療するためにプレドニゾロンまたはヒドロキシクロロキンと組み合わせるtlr7阻害剤 |
BR112022025920A2 (pt) | 2020-06-22 | 2023-01-10 | Bristol Myers Squibb Co | Tratamento de artrite reumatoide |
TW202214632A (zh) * | 2020-07-27 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吲哚稠環類衍生物、其製備方法及其在醫藥上的應用 |
WO2022111636A1 (zh) | 2020-11-26 | 2022-06-02 | 江苏恒瑞医药股份有限公司 | 稠合三环化合物、其制备方法及其在医药上的应用 |
IL307203A (en) | 2021-04-16 | 2023-11-01 | Gilead Sciences Inc | THIENOPYRROLE COMPOUNDS |
JP2024518558A (ja) | 2021-05-13 | 2024-05-01 | ギリアード サイエンシーズ, インコーポレイテッド | TLR8調節化合物と抗HBV siRNA治療薬との組合せ |
CN113416188B (zh) * | 2021-05-31 | 2022-12-13 | 河南偶联生物科技有限公司 | 一种[1,2,4]***并[1,5-a]吡啶化合物的合成方法 |
CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022298639A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2024015825A1 (en) | 2022-07-13 | 2024-01-18 | Bristol-Myers Squibb Company | Processes for preparing 5-bromo-3,4-dimethylpyridin-2-amine and 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6867200B1 (en) | 1998-12-18 | 2005-03-15 | Axys Pharmaceuticals, Inc. | (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors |
EA200600069A1 (ru) | 2003-06-20 | 2006-08-25 | Коли Фармасьютикал Гмбх | Низкомолекулярные антагонисты toll-подобных рецепторов (tlr) |
WO2006113458A1 (en) * | 2005-04-15 | 2006-10-26 | Bristol-Myers Squibb Company | Heterocyclic inhibitors of protein arginine methyl transferases |
AU2007234399A1 (en) | 2006-04-04 | 2007-10-11 | Myriad Genetics, Inc. | Compounds for diseases and disorders |
DE102006033109A1 (de) | 2006-07-18 | 2008-01-31 | Grünenthal GmbH | Substituierte Heteroaryl-Derivate |
US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
ATE495743T1 (de) | 2006-12-01 | 2011-02-15 | Galapagos Nv | Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten |
WO2008152471A1 (en) | 2007-06-12 | 2008-12-18 | Coley Pharmaceutical Group, Inc. | Quinazoline derivative useful as toll-like receptor antagonist |
WO2009030996A1 (en) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Triazole compounds as toll-like receptor (tlr) agonists |
FR2926556B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
EP2350032B1 (en) | 2008-09-26 | 2016-05-25 | Eisai R&D Management Co., Ltd. | Benzoxazole compounds and methods of use |
CA2738929A1 (en) | 2008-10-17 | 2010-04-22 | Boehringer Ingelheim International Gmbh | Heteroaryl substituted indole compounds useful as mmp-13 inhibitors |
RU2011137419A (ru) | 2009-02-11 | 2013-03-20 | Суновион Фармасьютикалз Инк. | Обратные агонисты и антагонисты гистамина н3 и способы их применения |
KR20120035183A (ko) | 2009-06-10 | 2012-04-13 | 선오비온 파마슈티컬스 인코포레이티드 | 히스타민 h3 역 작용제 및 길항제, 및 이의 사용 방법 |
TWI462920B (zh) * | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
EP2453895B1 (en) | 2009-07-16 | 2018-05-23 | Mallinckrodt LLC | (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
US9241991B2 (en) | 2010-10-21 | 2016-01-26 | The Brigham And Women's Hospital, Inc. | Agents, compositions, and methods for treating pruritus and related skin conditions |
PL2663555T4 (pl) | 2011-01-12 | 2017-08-31 | Ventirx Pharmaceuticals, Inc. | Podstawione benzoazepiny jako modulatory receptora toll-podobnego |
PL2663550T4 (pl) | 2011-01-12 | 2017-07-31 | Ventirx Pharmaceuticals, Inc. | Podstawione benzoazepiny jako modulatory receptora toll-podobnego |
CA2837207A1 (en) | 2011-06-01 | 2012-12-06 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
RU2606114C2 (ru) | 2011-06-01 | 2017-01-10 | Джейнус Байотерапьютикс, Инк. | Новые модуляторы иммунной системы |
KR101913619B1 (ko) | 2011-06-09 | 2018-12-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Gpr-119의 조절제로서의 신규한 화합물 |
WO2013009140A2 (en) | 2011-07-13 | 2013-01-17 | Sk Chemicals Co., Ltd. | 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors |
CA2850932A1 (en) | 2011-10-04 | 2013-04-11 | Janus Biotherapeutics, Inc. | Novel imidazole quinoline-based immune system modulators |
TWI619704B (zh) | 2012-05-18 | 2018-04-01 | 大日本住友製藥股份有限公司 | 羧酸化合物 |
JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
AU2014334554B2 (en) | 2013-10-14 | 2018-12-06 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
US9643967B2 (en) | 2013-12-13 | 2017-05-09 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors |
EP3398948A3 (en) | 2014-08-22 | 2018-12-05 | Janus Biotherapeutics, Inc. | 2,4,6,7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
US9550778B2 (en) | 2014-10-03 | 2017-01-24 | Vanderbilt University | Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5 |
EP3334745B1 (en) | 2015-08-13 | 2024-05-15 | Merck Sharp & Dohme LLC | Cyclic di-nucleotide compounds as sting agonists |
IL263934B2 (en) | 2016-06-29 | 2023-10-01 | Hanmi Pharm Ind Co Ltd | A derivative of glucagon, its conjugate, a preparation containing it and its medical use |
US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
SG11201811507YA (en) | 2016-06-29 | 2019-01-30 | Kezar Life Sciences | Crystalline salts of peptide epoxyketone immunoproteasome inhibitor |
AU2017307208B2 (en) | 2016-07-30 | 2021-01-21 | Bristol-Myers Squibb Company | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors |
EP3510024B1 (en) | 2016-09-09 | 2021-11-17 | Bristol-Myers Squibb Company | Pyridyl substituted indole compounds |
ES2909401T3 (es) | 2017-08-04 | 2022-05-06 | Bristol Myers Squibb Co | Compuestos de indol sustituidos útiles como inhibidores de TLR7/8/9 |
WO2019028301A1 (en) | 2017-08-04 | 2019-02-07 | Bristol-Myers Squibb Company | INDOLE COMPOUNDS SUBSTITUTED WITH [1,2,4] TRIAZOLO [4,3-A] PYRIDINYL |
WO2019099336A1 (en) | 2017-11-14 | 2019-05-23 | Bristol-Myers Squibb Company | Substituted indole compounds |
SG11202005513TA (en) | 2017-12-15 | 2020-07-29 | Bristol Myers Squibb Co | Substituted indole ether compounds |
US10544143B2 (en) | 2017-12-18 | 2020-01-28 | Bristol-Myers Squibb Company | 4-azaindole compounds |
EA202091483A1 (ru) | 2017-12-19 | 2020-10-28 | Бристол-Маерс Сквибб Компани | Амидзамещенные индольные соединения, пригодные в качестве ингибиторов tlr |
SG11202005696YA (en) | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | Substituted indole compounds useful as tlr inhibitors |
AU2018390543A1 (en) | 2017-12-19 | 2020-08-06 | Bristol-Myers Squibb Company | 6-azaindole compounds |
SG11202005733QA (en) | 2017-12-20 | 2020-07-29 | Bristol Myers Squibb Co | Diazaindole compounds |
US11420958B2 (en) | 2017-12-20 | 2022-08-23 | Bristol-Myers Squibb Company | Aryl and heteroaryl substituted indole compounds |
SG11202005694RA (en) | 2017-12-20 | 2020-07-29 | Bristol Myers Squibb Co | Amino indole compounds useful as tlr inhibitors |
US20210403468A1 (en) | 2018-10-24 | 2021-12-30 | Bristol-Myers Squibb Company | Substituted indole and indazole compounds |
-
2017
- 2017-06-27 US US15/635,055 patent/US10071079B2/en not_active Ceased
- 2017-06-28 SI SI201730890T patent/SI3478682T1/sl unknown
- 2017-06-28 EA EA201990048A patent/EA037530B1/ru not_active IP Right Cessation
- 2017-06-28 KR KR1020197002353A patent/KR102473482B1/ko active IP Right Grant
- 2017-06-28 HU HUE17737442A patent/HUE056091T2/hu unknown
- 2017-06-28 EP EP17737442.8A patent/EP3478682B1/en active Active
- 2017-06-28 JP JP2018568837A patent/JP6995067B6/ja active Active
- 2017-06-28 AU AU2017287902A patent/AU2017287902B2/en active Active
- 2017-06-28 SG SG11201811590RA patent/SG11201811590RA/en unknown
- 2017-06-28 RS RS20211090A patent/RS62292B1/sr unknown
- 2017-06-28 CA CA3029620A patent/CA3029620A1/en active Pending
- 2017-06-28 CN CN201780052726.1A patent/CN109641895B/zh active Active
- 2017-06-28 PL PL17737442T patent/PL3478682T3/pl unknown
- 2017-06-28 AR ARP170101788A patent/AR108905A1/es unknown
- 2017-06-28 TW TW106121570A patent/TWI636053B/zh active
- 2017-06-28 ES ES17737442T patent/ES2886964T3/es active Active
- 2017-06-28 PE PE2018003329A patent/PE20190324A1/es unknown
- 2017-06-28 UY UY0001037310A patent/UY37310A/es unknown
- 2017-06-28 BR BR112018077119-8A patent/BR112018077119A2/pt unknown
- 2017-06-28 DK DK17737442.8T patent/DK3478682T3/da active
- 2017-06-28 PT PT177374428T patent/PT3478682T/pt unknown
- 2017-06-28 LT LTEPPCT/US2017/039633T patent/LT3478682T/lt unknown
- 2017-06-28 MY MYPI2018002975A patent/MY196474A/en unknown
- 2017-06-28 MX MX2018015422A patent/MX2018015422A/es active IP Right Grant
- 2017-06-28 WO PCT/US2017/039633 patent/WO2018005586A1/en unknown
-
2018
- 2018-07-23 US US16/042,116 patent/US10478424B2/en not_active Ceased
- 2018-12-25 IL IL263961A patent/IL263961B/en active IP Right Grant
- 2018-12-27 CL CL2018003821A patent/CL2018003821A1/es unknown
-
2019
- 2019-01-24 CO CONC2019/0000686A patent/CO2019000686A2/es unknown
- 2019-01-28 ZA ZA2019/00571A patent/ZA201900571B/en unknown
- 2019-10-15 US US16/653,297 patent/US10912766B2/en not_active Ceased
-
2020
- 2020-12-07 US US17/113,495 patent/US11672780B2/en active Active
-
2021
- 2021-08-04 HR HRP20211261TT patent/HRP20211261T8/hr unknown
- 2021-09-15 CY CY20211100814T patent/CY1124514T1/el unknown
-
2022
- 2022-01-25 US US17/584,155 patent/USRE49893E1/en active Active
- 2022-01-25 US US17/584,147 patent/USRE49931E1/en active Active
- 2022-01-25 US US17/584,139 patent/USRE49880E1/en active Active
-
2023
- 2023-04-26 US US18/307,119 patent/US20230255941A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20211261T1 (hr) | [1,2,4]triazolo[1,5-a]piridinil supstituirani spojevi indola | |
HRP20231244T1 (hr) | Spoj 4-azaindola | |
JP2019523241A5 (hr) | ||
JP2021506858A5 (hr) | ||
IL248466A (en) | Tricyclic compounds for drug preparation | |
CO5700766A2 (es) | Antagonistas del receptor a2a de 2-alquinil-y 2-alquinil-pirazolo-[4,3-e]-1,2,4 triazolo-[1,5-c]-pirimidina adenosina | |
US7429664B2 (en) | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | |
US7902217B2 (en) | Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof | |
CA2081350A1 (en) | Isoquinoline amides and esters as 5 ht3 receptor antagonists | |
ES2291933T3 (es) | Tienopirroles como agentes antivirales. | |
RU2009127095A (ru) | Новые оксадиазольные соединения | |
HRP20171302T1 (hr) | Makrociklički derivati piridazinona | |
AR104447A1 (es) | Azabenzimidazoles y sus usos como moduladores de los receptores ampa | |
HRP20140437T1 (hr) | Bicikliäśki spojevi i njihove uporabe kao dualnih c-src/jak inhibitora | |
US20050209253A1 (en) | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group | |
AU2009288021A1 (en) | Macrocyclics pyrimidines as Aurora kinase inhibitors | |
RS54348B1 (en) | INHIBITORS NEPRILIZINA | |
GB1067471A (en) | Thioxanthenesulfonamides and preparation thereof | |
JP2013504543A5 (hr) | ||
YU46991B (sh) | Postupak za proizvodnju tricikličnih jedinjenja | |
ES8300762A1 (es) | Un procedimiento para la preparacion de benzamidas. | |
ZA835411B (en) | Novel cephalosporin compounds and preparation thereof | |
ES2089258T3 (es) | Derivados de 1,2,4-triazolo(1,5-a)pirimidina, procedimiento para prepararlos, asi como medicamentos que los contienen y utilizacion de los mismos. | |
GB2020975A (en) | Compositions containing cyanine compounds | |
IL97685A0 (en) | 2-(substituted pyrrolidinylthio)carbapenem derivatives |